Makoto Nishio
A5078287634- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Glycosylation and Glycoproteins Research
- RNA modifications and cancer
- Phytochemical Studies and Bioactivities
- Peptidase Inhibition and Analysis
- Cytokine Signaling Pathways and Interactions
- Pancreatic and Hepatic Oncology Research
- PI3K/AKT/mTOR signaling in cancer
- Esophageal Cancer Research and Treatment
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Nausea and vomiting management
- Chronic Lymphocytic Leukemia Research
- Head and Neck Cancer Studies
Japanese Foundation For Cancer Research
2016-2025
The Cancer Institute Hospital
2016-2025
Fudan University
2024
Shanghai Chest Hospital
2024
Southern Medical University
2024
Guangdong Academy of Medical Sciences
2024
Zhongshan Hospital
2024
Cancer Institute (WIA)
2014-2022
Thoracic Surgery Foundation
2020-2022
Yokohama City University
2018
Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.
Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine inhibitor (TKI) crizotinib. Herein, we report first preclinical evaluation of next-generation TKI, ceritinib (LDK378), in setting crizotinib resistance. An interrogation vitro and vivo models acquired crizotinib, including lines established from biopsies patients with crizotinib-resistant NSCLC, revealed that potently overcomes mutations. In...
Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and amplifications 1 6%. Capmatinib, a selective inhibitor of the receptor, has shown activity models various types activation.
RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with fusion-positive NSCLC, the efficacy and safety selective inhibition unknown.We enrolled advanced NSCLC who had previously received platinum-based chemotherapy those were untreated separately a phase 1-2 trial selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by independent review committee. Secondary points included duration...
IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement overall survival (OS) and progression-free (PFS) versus placebo CP/ET. Updated OS, disease progression patterns, safety, exploratory biomarkers (PD-L1,...
IntroductionWe report the final results of phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin pemetrexed (APP) in patients with nonsquamous NSCLC.MethodsChemotherapy-naive stage IV NSCLC without sensitizing EGFR ALK genetic alterations were randomized a one-to-one ratio to receive four six cycles (PP) APP every weeks, followed by maintenance therapy alone. Co-primary end points overall survival (OS) and investigator-assessed progression-free (PFS).ResultsThe...
IntroductionWe report the final overall survival (OS) analyses of atezolizumab-carboplatin-paclitaxel (ACP [experimental arm]) and OS data with approximately 39.8 months median follow-up atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) versus bevacizumab-carboplatin-paclitaxel (BCP) in chemotherapy-naive patients metastatic nonsquamous NSCLC phase 3 IMpower150 study (NCT02366143).MethodsIn this randomized, open-label (N = 1202), coprimary end points included investigator-assessed...
Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non-small-cell lung cancer (NSCLC), regardless of brain metastases status and or without prior therapy an inhibitor the ALK protein. Data are presented from a phase II trial (ASCEND-2) which safety were evaluated who had NSCLC previously treated at least one platinum-based chemotherapy experienced progression during crizotinib treatment as their last therapy.Patients advanced NSCLC, including those asymptomatic...
Some but not all patients with non-small-cell lung cancer (NSCLC) respond to treatment epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). We developed and tested the ability of a predictive algorithm based on matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) analysis pretreatment serum identify who are likely benefit from EGFR TKIs.Serum collected NSCLC before gefitinib or erlotinib were analyzed by MALDI MS. Spectra acquired independently at...
IntroductionIn CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) less (prespecified descriptive analysis). We report results minimum 4 years' follow-up.MethodsAdults previously untreated stage IV recurrent NSCLC were randomized (1:1:1) ipilimumab, nivolumab, (PD-L1 ≥1%); chemotherapy, <1%). Efficacy included OS and other measures. Safety timing...
Immune checkpoint blockade against programmed cell death 1 (PD-1) and its ligand PD-L1 often induces durable tumor responses in various cancers, including non–small lung cancer (NSCLC). However, therapeutic resistance is increasingly observed, the mechanisms underlying anti–PD-L1 (aPD-L1) antibody treatment have not been clarified yet. Here, we identified two unique secreted splicing variants, which lacked transmembrane domain, from aPD-L1–resistant NSCLC patients. These variants worked as...
We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy patients with metastatic non-small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD-L1) status.Adults stage IV/recurrent cancer without EGFR mutations or ALK alterations and PD-L1 ≥ 1% < (n = 1739) were randomly assigned. Patients assigned to first-line ipilimumab, alone, chemotherapy. chemotherapy, End points included exploratory for...
In the phase III CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; ≥10 mutations/megabase).To evaluate patient-reported outcomes (PROs) this population.Disease-related symptoms general health status were assessed using validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) EQ-5D,...